Sage Therapeutics, Inc. (SAGE)
Largest Insider Buys in Sector
SAGE Stock Price History Chart
SAGE Stock Performance
About Sage Therapeutics, Inc.
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a …
Insider Activity of Sage Therapeutics, Inc.
Over the last 12 months, insiders at Sage Therapeutics, Inc. have bought $0 and sold $0 worth of Sage Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Sage Therapeutics, Inc. have bought $1.15M and sold $519,413 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,000 shares for transaction amount of $37,279 was made by Barrett Elizabeth (director) on 2023‑08‑09.
List of Insider Buy and Sell Transactions, Sage Therapeutics, Inc.
| 2023-08-09 | director | 2,000 0.0032% | $18.64 | $37,279 | +3.37% | |||
| 2023-05-09 | director | 1,000 0.0017% | $50.50 | $50,500 | -58.11% | |||
| 2023-02-10 | Sale | director | 11,643 0.0193% | $44.61 | $519,413 | -41.08% | ||
| 2022-11-10 | President and CEO | 14,500 0.024% | $34.48 | $500,022 | +19.18% | |||
| 2022-05-05 | 8,000 0.0136% | $31.45 | $251,563 | +26.48% | ||||
| 2021-08-05 | President and CEO | 23,640 0.0401% | $43.15 | $1.02M | -10.58% | |||
| 2021-06-16 | director | 17,842 0.0311% | $56.05 | $999,983 | -24.87% | |||
| 2021-06-16 | President and CEO | 8,800 0.0154% | $56.32 | $495,627 | -24.87% | |||
| 2021-06-16 | director | 1,810 0.0031% | $55.10 | $99,735 | -24.87% | |||
| 2019-12-09 | Chief Scientific Officer | 25,000 0.0494% | $64.16 | $1.6M | -16.96% | |||
| 2019-12-09 | President & CEO | 7,500 0.0148% | $64.20 | $481,500 | -16.96% | |||
| 2019-08-15 | Sale | director | 8,000 0.0154% | $160.58 | $1.28M | -58.68% | ||
| 2019-05-29 | Sale | President & CEO | 1,075 0.0021% | $170.61 | $183,401 | -20.75% | ||
| 2019-05-28 | Sale | President & CEO | 84,661 0.1656% | $174.83 | $14.8M | -20.45% | ||
| 2019-05-24 | Sale | President & CEO | 40,356 0.0786% | $175.08 | $7.07M | -20.51% | ||
| 2019-05-23 | Sale | President & CEO | 53,908 0.1047% | $174.51 | $9.41M | -20.45% | ||
| 2019-05-22 | Sale | Chief Business Officer | 25,000 0.0485% | $175.00 | $4.38M | -20.71% | ||
| 2019-05-10 | Sale | SVP, GC & Secretary | 15,000 0.0293% | $166.14 | $2.49M | -15.12% | ||
| 2019-05-06 | Sale | director | 8,000 0.0148% | $162.22 | $1.3M | -17.11% | ||
| 2019-03-21 | Sale | director | 7,879 0.0166% | $161.04 | $1.27M | -1.30% |
Insider Historical Profitability
| STARR KEVIN P | director | 320659 0.5242% | $5.50 | 1 | 4 | <0.0001% |
| Robichaud Albert | Chief Scientific Officer | 136400 0.223% | $5.50 | 2 | 6 | +14.96% |
| PAUL STEVEN M | director | 122400 0.2001% | $5.50 | 1 | 14 | +46.89% |
| JONAS JEFFREY M | director | 121981 0.1994% | $5.50 | 3 | 10 | <0.0001% |
| Greene Barry E | President and CEO | 46940 0.0767% | $5.50 | 3 | 0 | <0.0001% |
Institutional Investor Ownership
| Fidelity Investments | $109.97M | 9.75 | 5.87M | +7.04% | +$7.23M | 0.01 | |
| The Vanguard Group | $107.78M | 9.56 | 5.75M | +8.12% | +$8.1M | <0.01 | |
| RTW Investments, LP | $102.71M | 9.11 | 5.48M | +5.46% | +$5.31M | 1.54 | |
| BlackRock | $91.68M | 8.13 | 4.89M | +4.89% | +$4.28M | <0.01 | |
| Wellington Management Company | $89.06M | 7.9 | 4.75M | -21.61% | -$24.55M | 0.02 |